Godavari Drugs Ltd (530317)

Godavari Drugs Limited has submitted its quarterly statement of deviation or variation under Regulation 32 for the quarter ended September 30, 2026. The company confirmed that there has been no deviation or variation in the utilisation of funds raised through its preferential issue from the stated objects. The statement was reviewed by the Audit Committee and taken on record by the Board of Directors on November 11, 2026.

• Quarter ended: September 30, 2026
• Deviation or variation reported: Nil
• Funds raised via: Preferential issue
• Board and Audit Committee approval date: November 11, 2026

Godavari Drugs reported a modest 5.9% YoY increase in revenue from operations to ₹28.23 crore for the quarter ended September 30, 2026, compared to ₹26.65 crore in Q2 FY26. Net profit declined by 4.3% YoY to ₹0.96 crore from ₹1.00 crore in the previous year's corresponding quarter, weighed down by higher employee costs and other expenses. Sequentially, revenue was up 1.0% from ₹27.96 crore in Q1, while PAT declined 13.7% from ₹1.11 crore. Diluted EPS for the quarter dropped to ₹0.90 compared to ₹1.33 in Q2 FY26, partly driven by equity base expansion to ₹10.91 crore.

• Revenue from operations grew 5.9% YoY to ₹2,822.60 lakhs from ₹2,664.94 lakhs
• Net profit declined 4.3% YoY to ₹95.72 lakhs compared to ₹100.07 lakhs
• Operating profit before tax stood at ₹123.05 lakhs vs ₹112.15 lakhs in Q2 FY26
• Paid-up equity share capital expanded to ₹1,091.41 lakhs vs ₹753.05 lakhs in Q2 FY26, diluting EPS to ₹0.90
• H1 FY27 revenue reached ₹5,618.32 lakhs with net profit of ₹206.63 lakhs

Godavari Drugs approved the allotment of 7,86,690 equity shares to the promoter category following the conversion of warrants issued on a preferential basis. The allotment was done at an issue price of ₹89 per share (including a ₹79 premium) upon receipt of the 75% balance payment of ₹5.25 crore. Following this conversion, the company's paid-up equity capital increased from ₹10.91 crore to ₹11.70 crore. The infusion represents approximately 5.3% of the company's market cap of ₹99 crore.

• Allotment of 7,86,690 equity shares upon conversion of warrants to promoter category
• Conversion price of ₹89 per share, including a premium of ₹79 per share
• Receipt of balance 75% consideration totaling ₹5,25,11,557.50
• Paid-up equity share capital increases from 1,09,14,125 shares to 1,17,00,815 shares

Godavari Drugs Limited has secured board approval to avail working capital facilities aggregating up to ₹34.00 crore (₹340 million) from ICICI Bank Limited, based on a Credit Arrangement Letter dated October 12, 2026. This credit line is substantial relative to the company's size, representing approximately 30.9% of its TTM revenue (₹110 crore) and about 44.7% of its existing total debt (₹76 crore). The facility includes temporary overdraft accommodations and will require the creation of security. Managing Director Mukund Kakani was authorized to finalize and execute the documentation.

• Board approved working capital limits of up to ₹340.00 Million (₹34.00 crore) from ICICI Bank
• Facility sanctioned pursuant to Credit Arrangement Letter dated October 12, 2026
• Limit represents ~30.9% of TTM revenue of ₹110 crore
• Board authorized MD Mukund Kakani to execute facility agreements and create required security

Godavari Drugs Ltd's Board approved an amendment to its Memorandum of Association (MOA) to insert a new Main Object clause enabling entry into nutraceuticals, dietary supplements, natural extracts, and food ingredients. The expansion covers domestic and export marketing, own manufacturing, and third-party contract manufacturing. The proposed amendment is subject to shareholder approval via a Special Resolution at the 38th AGM scheduled for September 25, 2026.

• Board approved insertion of Main Object No. 4 under Clause III(A) on 31.08.2026 to include nutraceuticals, health supplements, and food ingredients
• Covers own manufacturing, contract manufacturing, and loan licensing for both domestic and export markets
• Shareholder approval scheduled to be sought at the 38th AGM on Friday, 25th September, 2026
• Amendment takes effect post-AGM approval and filing of Form MGT-14 with ROC Telangana

Godavari Drugs Limited has submitted its Statement on Deviation or Variation in the utilisation of funds for the quarter ended 30 June 2026, pursuant to Regulation 32 of SEBI (LODR) Regulations, 2015. The statement was previously reviewed and approved by the Board of Directors in its meeting held on 14 August 2026. This is a standard quarterly regulatory compliance filing.

• Filing pertains to Statement on Deviation or Variation for the quarter ended 30 June 2026
• Statement was considered and approved by the Board of Directors on 14 August 2026
• Submitted pursuant to Regulation 32 of SEBI (LODR) Regulations, 2015

Godavari Drugs reported a 17.4% YoY increase in revenue to ₹27.96 Cr for the quarter ended June 30, 2026. Net profit grew 6.7% YoY to ₹1.11 Cr, although it saw a sequential decline of 14% from the March 2026 quarter (₹1.29 Cr). Notably, EPS decreased to ₹1.10 from ₹1.38 in the year-ago period due to an increase in paid-up equity capital from ₹7.53 Cr to ₹10.13 Cr. The company continues to operate with tight margins, with total expenses accounting for 96% of total revenue.

• Revenue from operations increased 17.4% YoY to ₹27.96 Cr from ₹23.81 Cr.
• Net profit for the quarter stood at ₹1.11 Cr, up from ₹1.04 Cr in June 2025.
• Paid-up equity share capital rose to ₹10.13 Cr from ₹7.53 Cr YoY, leading to EPS dilution.
• Finance costs decreased slightly to ₹0.90 Cr compared to ₹1.00 Cr in the same quarter last year.
• Total expenses rose to ₹26.93 Cr, driven largely by cost of materials consumed at ₹26.15 Cr.

Godavari Drugs Ltd has issued a corrigendum to its previous intimation regarding the board meeting to approve Q1 FY27 results. The company clarified that the meeting will be held on August 14, 2026, correcting a typographical error that previously stated August 24, 2026. This meeting is critical for the small-cap company (Rs 84 Cr market cap) to report its performance for the quarter ended June 30, 2026. Investors should note the company's TTM revenue stands at Rs 106 Cr with a debt-to-equity ratio of 1.0.

• Board meeting date corrected to August 14, 2026, from the previously misstated August 24, 2026.
• The meeting is convened to consider and approve Un-Audited Financial Results for the quarter ended June 30, 2026.
• The correction follows an inadvertent typographical error in the intimation letter dated August 10, 2026.
• Company maintains a TTM revenue of Rs 106 Cr and a TTM PAT of Rs 4 Cr as of the latest financial context.

Godavari Drugs has scheduled a board meeting for August 14, 2026, to approve its unaudited financial results for the quarter ended June 30, 2026. The company enters this quarter following a TTM revenue of Rs 106 Cr and a PAT of Rs 4 Cr. Investors will be monitoring if the company can maintain the revenue momentum seen in the March 2026 quarter (Rs 33.16 Cr). The company currently operates with a high debt-to-equity ratio of 1.00, with total debt standing at Rs 76 Cr.

• Board meeting scheduled for August 14, 2026, to approve Q1 FY27 results
• Trading window for insiders has been closed since July 1, 2026
• Company reported a TTM PAT of Rs 4 Cr on a revenue base of Rs 106 Cr
• Promoter holding saw a significant decrease from 52.61% in Dec 2025 to 40.23% in Mar 2026